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Abstract
The Gram-positive bacterium Lactococcus lactis produces two distinct multidrug transporters, designated LmrA and LmrP, that both
confer resistance to a wide variety of cationic lipophilic cytotoxic compounds as well as to many clinically relevant antibiotics. While LmrP
is a proton/drug antiporter that belongs to the major facilitator superfamily of secondary transporters, LmrA is an ATP-dependent primary
transporter that belongs to the ATP-binding cassette superfamily of transport proteins. Both LmrA and LmrP function as ‘‘hydrophobic
vacuum cleaners’’ by excreting lipophilic cationic compounds from the inner leaflet of the membrane directly into the external water phase.
LmrA is both functionally and structurally homologous to the human multidrug transporter P-glycoprotein. LmrA is a half ABC transporter
that is functional as a homodimer, consistent with the general four-domain organization of ABC transporters, and is proposed to mediate drug
transport by an alternating two-site transport mechanism.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Microorganisms are almost continuously exposed to
numerous environmental toxins ranging from natural com-
pounds (e.g. plant alkaloids), peptides (e.g. bacteriocins) and
noxious metabolic products (e.g. bile salts and fatty acids in
the case of enteric bacteria), to industrially produced chem-
icals such as organic solvents and antibiotics. Microorgan-
isms have developed several mechanisms to resist the toxic
effects of antimicrobial agents, and drug-resistant pathogens
are on the rise. A major mechanism of resistance involves the
active extrusion of antimicrobials from the cell by drug
transport systems. Some of these drug excretion systems
mediate the extrusion of a given drug or class of drugs. In
contrast to these specific drug resistance (SDR) transporters,
the so-called multidrug resistance (MDR) transporters can
handle a wide variety of structurally unrelated compounds.
On the basis of bioenergetic and structural criteria, multidrug
transporters can be divided into two major classes: (i)
secondary transporters that are driven by a proton or sodium
motive force and (ii) ATP-binding cassette (ABC) primary
transporters, which use the hydrolysis of ATP to fuel trans-
port (for a recent review, see Ref. [1]).
In the Gram-positive bacterium Lactococcus lactis, an
organism broadly used in food manufacturing, two distinct
MDR transporters mediate resistance to toxic hydrophobic
cations and antibiotics. One MDR transporter, designated
LmrP, is a proton/drug antiport system, while the second
MDR transporter, designated LmrA, is an ATP-dependent
primary ABC transporter (Fig. 1). Hence, LmrP and LmrA
exemplify the two major classes of multidrug transporters
found in bacteria. Growth of L. lactis in the presence of
increasing concentrations of toxic compounds results in an
increase in energy-dependent drug-extrusion, suggesting that
the expression of these transporters is upregulated [2]. When
one of the transporters is deleted, the expression of the other
MDR transporter is increased. So far, attempts to delete both
MDR transporter genes have been unsuccessful, emphasiz-
ing the important role of these proteins for the viability of L.
lactis, even in media to which no toxic compounds have
been added. In addition to LmrA and LmrP, which are
involved in the excretion of lipophilic cations, L. lactis also
possesses two MDR transporters that mediate the extrusion
of anionic antimicrobial compounds [3,4]. The genes encod-
ing the latter two MDR transporters have not been cloned
yet, but with the availability of the L. lactis genome sequence
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these genes will soon be identified. This review summarizes
the existing data only of the two well-studied multidrug
transporters LmrA and LmrP.
2. The secondary MDR transporter LmrP
LmrP is a 408-amino acid-long membrane protein that
belongs to the major facilitator superfamily (MFS) of sec-
ondary transporters. Based on its hydrophobicity profile, the
‘‘positive inside rule,’’ and the homology for better charac-
terized MFS transporters, a secondary structure model was
constructed for LmrP [5]. This model predicts that LmrP
contains 12 transmembrane segments (TMS), linked by
cytosolic and external loop regions, with the N- and C-
termini facing the cytoplasm (Fig. 2). LmrP has a broad
substrate specificity and can handle a wide variety of lip-
ophilic cationic toxins such as ethidium, rhodamine 123,
daunomycin, and tetraphenylphosphonium (TPP + ) [2,5,6].
Interestingly, the transporter also confers resistance to sev-
eral broad-spectrum antibiotics belonging to the classes of
lincosamides, macrolides, streptogramins and tetracyclines
[7]. Transport experiments in intact cells and in inside-out
membrane vesicles demonstrated that extrusion of cationic
drugs by LmrP is driven by both the membrane potential and
the transmembrane proton gradient, indicating that LmrP
mediates electrogenic nH + /drug (nz 2) antiport [5,6,8].
LmrP can be functionally overexpressed in L. lactis using
the tightly regulated, nisin-controlled expression (NICE)
system [9]. Proton motive force (pmf)-dependent drug
efflux by LmrP in inside-out membrane vesicles was
inhibited by low concentrations of detergents, such as Triton
X-100, Triton X-114, and Tween 80, that did not affect the
magnitude or composition of the pmf. This finding restricted
the range of compounds that could be used for the solubi-
lization and reconstitution of the protein, because low
concentrations of detergent are retained in proteoliposomes.
However, dodecyl maltoside did not modulate the activity of
LmrP, and this detergent was therefore used to solubilize
and functionally reconstitute the protein in dodecyl malto-
side-destabilized, preformed liposomes composed of
Escherichia coli phospholipids and egg phosphatidyl chol-
ine [9]. Purified and reconstituted LmrP mediated the trans-
port of multiple drugs in response to an artificially imposed
pH gradient, demonstrating that this efflux pump functions
independent of accessory proteins [9].
Most drugs that interact with multidrug transporters such
as LmrP readily intercalate into the lipid bilayer due to their
high hydrophobicity and amphiphilic nature. Drug extrusion
by LmrP (and also by LmrA, see below) occurs from the
membrane, rather than from the cytoplasm. This is evident
from the observation that the non-fluorescent compound
BCECF-AM is excreted from LmrP-producing cells prior to
hydrolysis into the fluorescent cellular indicator BCECF by
intracellular esterases [8]. The most convincing evidence for
drug efflux from the membrane to the aqueous phase is
provided by the kinetics of TMA-DPH transport by LmrP
and LmrA [8,10]. TMA-DPH partitions readily into the lipid
bilayer. It is strongly fluorescent when partitioned into the
membrane but essentially non-fluorescent in an aqueous
environment, which makes it possible to fluorimetrically
follow the partitioning of TMA-DPH into the lipid bilayer.
The increase in fluorescence intensity due to the partitioning
of TMA-DPH into the phospholipid bilayer was found to be
a biphasic process (Fig. 3) [8]. A rapid process that reflects
Fig. 1. Schematic representation of two multidrug transporters found in L.
lactis. The ABC-type primary multidrug transporter LmrA and the
secondary multidrug transporter LmrP exemplify the two major classes of
multidrug transporters found in bacteria.
Fig. 2. Secondary structure model of LmrP. The charged amino acid residues are indicated.
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the fast entry (1–2 s) of TMA-DPH into the outer leaflet of
the phospholipid bilayer is followed by a slower (several
minutes) transbilayer movement from the outer to the inner
leaflet of the membrane. Energization of intact cells by the
addition of glucose revealed that the initial rate of extrusion
of TMA-DPH, monitored as a decrease in fluorescence over
time, increased with an increasing concentration of TMA-
DPH in the inner leaflet of the membrane (Fig. 3A) [8]. The
extent of extrusion never exceeded the amount of TMA-
DPH present in the inner leaflet, indicating that the probe
cannot be extruded from the outer leaflet of the cytoplasmic
membrane. When similar experiments were done with
inside-out membrane vesicles, with the inner leaflet now
immediately accessible to drug molecules, the situation was
significantly different (Fig. 3B). Upon addition of TMA-
DPH to the membrane vesicle suspension, TMA-DPH
rapidly intercalates into the exposed leaflet of the mem-
brane, resulting in a maximum concentration of TMA-DPH
in this leaflet. Upon energization maximal rates of TMA-
DPH extrusion were observed at any moment after addition
of TMA-DPH and the extent of extrusion, in contrast to
intact cells, now exceeded the amount of TMA-DPH present
in the internal leaflet of inside-out vesicles (Fig. 3B). These
observations strongly indicate that TMA-DPH is recognized
as substrate only after partitioning into the normal inner
leaflet of the cellular membrane, and is directly transported
to the aqueous environment as observed by the decrease in
fluorescence. These observations indicate that LmrP func-
tions by a vacuum cleaner mechanism (Fig. 4) [10].
Interestingly, the kinetic analysis of inhibition of LmrP-
mediated Hoechst 33342 transport by drug molecules
revealed competitive inhibition by quinine and verapamil,
non-competitive inhibition by nicardipin and vinblastin, and
uncompetitive inhibition by TPP + [6]. These findings are
indicative for the presence of multiple drug interaction sites
in this multidrug transport protein. Understanding the molec-
ular basis of multidrug recognition by LmrP is a major goal.
According to the predicted membrane topology (Fig. 2), the
Fig. 3. Rate of energy-dependent TMA-DPH extrusion in the course of
TMA-DPH partitioning in the phospholipid bilayer. Proton motive force-
dependent TMA-DPH fluorescence development in L. lactis cells expressing
LmrP (A) and in inside-out (ISO) membrane vesicles prepared from E. coli
cells in which LmrP has been expressed (B). The kinetics of TMA-DPH
fluorescence development upon the addition to membranes is biphasic. The
initial fast phase reflects probe partitioning in the outer leaflet of the
membrane, while the second slower phase is due to the transbilayer
movement of TMA-DPH into the inner leaflet of the membrane. Cells were
energized with 25 mM of glucose at 0, 5 and 15 min after the addition of 100
nM of TMA-DPH. In cells, the initial rate of TMA-DPH extrusion increases
in the course of probe flipping from the outer to inner leaflet of the
membrane, whereas the steady state TMA-DPH fluorescence remains the
same (A). The ISO membrane vesicles were energized with 10 mM D-lactate
at 0, 2, 5 and 10 min after the addition of 100 nM TMA-DPH. In the vesicles,
the initial transport rates were identical and independent of the partitioning
of TMA-DPH into the inner leaflet of the inverted membrane vesicles (B).
The steady state fluorescence in this experiment increased along with the
partitioning of TMA-DPH into the internal leaflet of the inverted
membranes. Data obtained from Ref. [8].
Fig. 4. Vacuum cleaner mechanism of drug transport across the cytoplasmic
membrane. The lipophilic cytotoxic compounds intercalate rapidly in the
outer leaflet of the membrane. Subsequently, the compound flips slowly
from the outer leaflet to the inner leaflet of the membrane from where they
can diffuse into the cytosol. The MDR pump interacts with the cytotoxic
compound in the inner leaflet of the membrane and excretes the compound
by an energy-dependent process directly into the external water phase.
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putative TMS of LmrP are very hydrophobic and contain
three charged residues, D142, E327, and E388, which are
located in TMS V, X, and XII, respectively. Cysteine scan-
ning mutagenesis, in combination with thiol chemistry, of all
acidic residues in LmrP provided strong evidence that except
for D142, E327, and E388, no other negatively charged
residues are present in the membrane-embedded domain of
LmrP. Site-directed mutagenesis and transport experiments
revealed that the negative charges at positions 142 and 327
are important for the recognition of some cationic drugs by
LmrP [26].
3. The primary ABC-type MDR transporter LmrA
From the energetics in vivo it is clear that the chromo-
somally located lmrA gene encodes an ATP-coupled pri-
mary efflux pump [2]. Most importantly, LmrA is inhibited
by ortho-vanadate, an inhibitor of ABC transporters and P-
type ATPases, but not upon dissipation of the pmf [2,10]. In
vitro, isolated membrane vesicles and proteoliposomes, in
which purified LmrA was reconstituted, were employed to
prove that transport of multiple drugs was LmrA- and ATP-
dependent [11,12]. Hydropathy analysis of the 590 amino
acid LmrA protein suggests a putative topology of six
membrane spanning regions (putative a-helices) in the
amino-terminal hydrophobic domain, followed by a large
hydrophilic domain containing the ATP-binding site [11]
(Fig. 5). Recent studies involving cysteine scanning muta-
genesis (G.J. Poelarends and W.N. Konings, unpublished
results) and Attenuated Total Reflection Fourier Transform
Infrared Spectroscopy (ATR-FTIR) [13] have provided
strong experimental evidence that the membrane spanning
regions of LmrA are indeed a-helices. The nucleotide bind-
ing domain (NBD) of LmrA contains features diagnostic of
an ABC-type ATPase, such as the ABC signature sequence
and the Walker A and B motifs [11]. In view of the general
four-domain organization of ABC transporters, consisting of
two transmembrane domains (TMDs) and two NBDs [14],
LmrA appears to be a half transporter. This suggests that
LmrA might function as a homodimer to form a full trans-
porter with four core domains. Several lines of evidence
convincingly demonstrated that this is indeed the case
(reviewed in Ref. [15]).
The 65 kDa LmrA protein shares significant sequence
similarity with members of the P-glycoprotein subfamily of
ABC transporters, most notably the human MDR P-glyco-
protein. LmrA and each half of P-glycoprotein (MDR1) share
34% identical residues and an additional 16% of conservative
substitutions [11]. The sequence conservation in the TMD of
LmrA includes particular regions (e.g. the region comprising
transmembrane helices 5 and 6), which have been implicated
as being involved in drug binding by MDR1 [16]. Interest-
ingly, LmrA shares 28% overall sequence identity with the
lipid flippase MsbA from E. coli, the structure of which was
recently determined by X-ray crystallography to a resolution
of 4.5 A˚ [17].
As pointed out for LmrP, LmrA was also shown to
function as a ‘‘hydrophobic vacuum cleaner,’’ which
extrudes toxic lipophilic compounds from the inner leaflet
of the lipid bilayer directly into the external water phase [10].
Its classification as a multidrug transporter is evident from its
currently known spectrum of substrates. LmrA substrates
include anticancer drugs such as vinca alkaloids (vinblastine,
vincristine) and anthracyclines (daunomycin, doxorubicin),
or cytotoxic agents such as antimicrotubule drugs (colchi-
cine) and DNA intercalators (ethidium bromide), or toxic
peptides (valinomycin, nigericin), fluorescent membrane
probes (Hoechst 33342, diphenyl-hexatriene), and fluores-
cent dyes such as rhodamine 6G and rhodamine 123
[11,12,15,18,19]. LmrA modulators (i.e. compounds that
reverse LmrA-mediated multidrug resistance) are also struc-
turally unrelated to each other and include calcium channel
blockers (e.g. verapamil), 1,4-dihydropyridines (e.g. nicar-
dipine), indolizine sulfones (e.g. SR33557), antimalarials
(e.g. quinine and quinidine), immunosuppressants (e.g.
cyclosporin A), and the Rauwolfia alkaloid reserpine
[11,19].
To address the role of LmrA in antibiotic resistance, the
lmrA gene was expressed in E. coli strain CS1562, which is
hypersensitive to drugs due to a deficiency of the TolC porin.
LmrA producing cells showed an increased resistance to 17
out of 21 clinically most used antibiotics, including broad-
spectrum antibiotics belonging to the classes of aminoglyco-
sides, lincosamides, macrolides, quinolones, streptogramins
and tetracyclines (Table 1) [20]. This further demonstrates the
remarkable broad substrate specificity of LmrA. In addition,
it has recently been demonstrated that purified and reconsti-
tuted LmrA can also transport phospholipids [12].
The functional similarity between bacterial LmrA and
human P-glycoprotein is exemplified by their currently
known spectrum of substrates, consisting mainly of hydro-
phobic cations. Another interesting aspect is that LmrA,
when overexpressed in insect and human lung fibroblast
Fig. 5. Topology model for LmrA. The LmrA protein is predicted to contain
a TMD with six transmembrane a-helices, and a NBD with the ABC
signature and Walker A/B sequences.
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cells, is able to functionally complement P-glycoprotein
[21]. Surprisingly, LmrA was targeted to the plasma mem-
brane and conferred typical multidrug resistance on the
human cells. The pharmacological characteristics of LmrA
and P-glycoprotein expressed in lung fibroblast cells were
very similar [21]. This remarkable conservation of function
between these two ABC-type multidrug transporters implies
a common overall structure and transport mechanism.
Several lines of evidence convincingly demonstrated that
each homodimer of LmrA contains a low-affinity drug-
binding site that is allosterically coupled to a high-affinity
drug-binding site [22]. The dissociation constants for the two
vinblastine-binding sites are approximately 150 and 30 nM
vinblastine, respectively. These drug-binding sites appear to
be directly involved in drug transport as shown by the
reciprocal stimulation of LmrA-mediated vinblastine and
Hoechst 33342 transport at low drug concentrations, and
reciprocal inhibition at high drug concentrations [22]. The
obligatory link between the drug-binding and catalytic cycles
has been shown by vanadate-trapping experiments [22]. It
was found that of the two vinblastine-binding sites accessible
in the LmrA transporter, only the low-affinity vinblastine-
binding site is accessible in the vanadate-trapped transition
state conformation of LmrA. In addition, specific photo-
affinity labelling of the vanadate-trapped LmrA transporter
with [3H]-APDA, a drug that can be transported by LmrA,
was obtained in right-side-out membrane vesicles, but not in
inside-out membrane vesicles, demonstrating that the low-
affinity drug-binding site is exposed to the outside (extrac-
ellular) surface of the cell membrane. The vanadate-trapped
conformation of LmrA, with a single low-affinity drug-
binding site exposed to the extracellular surface, is consistent
with the hypothesis that an ATP hydrolysis-induced con-
formational change moves a high-affinity drug-binding site
from the inside of the membrane to the outside with a
concomitant change to a low affinity site [22,23]. Indeed,
conformational changes in LmrA upon hydrolysis of ATP
have been detected by ATR-FTIR spectroscopy [24].
The substrate-binding data obtained with (vanadate-trap-
ped) LmrA, when combined with the alternating catalytic
site model, in which the ABC domains of P-glycoprotein act
alternately to hydrolyze ATP [25], led to the proposition of
an alternating two-site transport model [22,23] (Fig. 6). This
model predicts that in a complete drug transport cycle, each
monomer of the LmrA dimer alternates its drug-binding site
from high affinity to occluded state to low affinity and back
to high affinity. The affinities of the binding-sites in the
Fig. 6. Alternating two-site transport model. Rectangles represent the
transmembrane domains of LmrA. Circles, squares and hexagons represent
different conformations of the NBDs. The ATP-bound (circle) state is
associated with a high-affinity drug-binding site on the inside of the
transporter. The ADP-bound (square) state is associated with a low-affinity
drug-binding site on the outside of the transporter. The ADP-Pi (hexagonal)
state is associated with an occluded drug-binding site, and represents the
ADP/vanadate-trapped form of the ABC domain. According to the model,
the transporter oscillates between two configurations, each containing a high
affinity, inside-facing, transport-competent drug-binding site, and a low
affinity, outside-facing drug-release site. The ATP-dependent interconver-
sion of one configuration into the other proceeds via a catalytic transition
state conformation in which the transport-competent site is occluded.
Table 1
Effect of LmrA expression in E. coli CS1562 on the relative resistance to
antibioticsa
Class Antibiotic Relative
resistance (fold)
Aminoglycosides gentamicin 2
kanamycin 3
h-Lactams ampicillin 2
ceftazidime 3
meropenem 1
penicillin 4
Glycopeptides vancomycin 1
Lincosamides clindamycin 14
Macrolides azithromycin 33
clarithromycin 23
dirithromycin 264
erythromycin 53
roxithromycin 35
spiramycin 35
Quinolones ciprofloxacin 2
ofloxacin 4
Streptogramins dalfopristin 163
quinupristin 31
RP59500 55
Tetracyclines chlortetracycline 28
demeclocycline 12
minocycline 138
oxytetracycline 8
tetracycline 14
Others chloramphenicol 11
trimethoprim 1
a Relative resistances were determined by dividing the IC50 (the
antibiotic concentration required to inhibit the growth rate by 50%) for cells
harboring pGKLmrA, by the IC50 for control cells harboring pGK13.
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monomers alternate: when the drug-binding site in one
monomer is in the high affinity state the binding site in
the other monomer is in a low affinity state and vice versa.
Hence, this process is called ‘‘an alternating two-site mech-
anism’’. Such a scenario implies that both halves of the
apparently symmetric LmrA transporter are able to act
asymmetrically. However, it is presently not clear whether
the binding sites are present in separate TMDs or at the
interface between TMDs.
4. Conclusions and perspectives
Studies on bacterial MDR transporters are relevant
because during the past years it has become evident that
MDR activities are involved in the ongoing emergence of
antibiotic resistance in pathogenic bacteria. Although L.
lactis is considered to be non-pathogenic and safe to use
in starter cultures for cheese production, the exceptionally
broad antibiotic specificity of LmrP and LmrA, the possible
transfer of the lmrP and lmrA genes to other bacteria in food
or the digestive tract, and the presence of homologues in
pathogenic microorganisms [15,18], provide a serious threat
to the efficacy of valuable antibiotics. In addition, LmrA is
able to complement the human MDR P-glycoprotein, sup-
porting the clinical and academic value of studying these
bacterial proteins.
Transport of cytotoxic drugs from the cytoplasmic leaflet
of the membrane appears to be the most efficient way in
which MDR transporters can prevent toxic compounds from
entering the cytoplasm. Drug molecules reaching the cell
rapidly insert into the outer leaflet of the membrane, but
flipping of the drug molecules from the outer to inner leaflet
is slow and the rate-limiting step in entry. LmrP and LmrA
are able to transport drug molecules from the inner leaflet
back into the external medium, counteracting the rate-limit-
ing step in drug entry. If these transporters would transport
drugs from the outer leaflet of the membrane, they would
probably not be able to compete with the high rate at which
drug molecules enter this leaflet. Drug molecules would
‘‘escape’’ into the inner leaflet and subsequently enter the
cytoplasm.
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